Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia.

Saved in:
Bibliographic Details
Title: Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia.
Authors: Morató X; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Puerta R; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Universitat de Barcelona (UB), Spain., Cano A; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Spain., Orellana A; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., de Rojas I; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Capdevila M; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Spain., Montrreal L; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Rosende-Roca M; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., García-González P; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Olivé C; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., García-Gutiérrez F; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Blázquez J; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Miguel A; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Núñez-Llaves R; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Pytel V; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Alegret M; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Fernández MV; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain., Marquié M; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Valero S; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Cavazos JE; South Texas Medical Science Training Program, University of Texas Health San Antonio, San Antonio, TX, USA.; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA., Mañes S; Department of Immunology and Oncology, Centro Nacional Biotecnología (CNB-CSIC), 28049, Madrid, Spain., Boada M; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., Cabrera-Socorro A; Neuroscience Therapeutic Area, Drug Discovery, Johnson & Johnson Innovative Medicine, USA., Ruiz A; Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.
Source: Brain, behavior, & immunity - health [Brain Behav Immun Health] 2024 Nov 16; Vol. 42, pp. 100899. Date of Electronic Publication: 2024 Nov 16 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101759062 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3546 (Electronic) Linking ISSN: 26663546 NLM ISO Abbreviation: Brain Behav Immun Health Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3546
DOI:10.1016/j.bbih.2024.100899